H. Christomanou

发表

Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant.

R. Linke, H. Christomanou, A. Aignesberger, 1986, Biological chemistry Hoppe-Seyler.

Activator protein deficient Gaucher's disease

A. Chabás, H. Christomanou, T. Pàmpols, 1989, Klinische Wochenschrift.

Isoelectric focusing pattern of acid hydrolases in cultured fibroblasts, leucocytes and cell-free amniotic fluid.

K. Sandhoff, H. Christomanou, C. Čáp, 1977, Neuropadiatrie.

Biochemistry and Genetics of gangliosidoses

K. Sandhoff, H. Christomanou, 2004, Human Genetics.

Etiology of a New Identified Gaucher Disease Variant without Glucosylceramidase Defect

N. Herschkowitz, U. Wiesmann, H. Christomanou, 1988 .

Deficient ferritin immunoreactivity in tissues from niemann-pick type C patients: extension of findings to fetal tissues, H and L ferritin isoforms, but also one case of the rare Niemann-Pick C2 complementation group.

W. Kleijer, P. Arosio, M. Vanier, 2000, Molecular genetics and metabolism.

Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant

F. Sanmartí, M. Pineda, I. Ferrer, 1999, Acta Neuropathologica.

An atypical variant of Fabry's disease with manifestations confined to the myocardium.

C. Eng, R. Desnick, E. Erdmann, 1991, The New England journal of medicine.

Leptomeningeal lipid storage patterns in Fabry disease

M. Elleder, K. Harzer, B. Kustermann-Kuhn, 2004, Acta Neuropathologica.

A family with visceral course of Niemann-Pick disease, macular halo syndrome and low sphingomyelin degradation rate

E. Steichen‐Gersdorf, W. Sperl, M. Vanier, 1994, Journal of Inherited Metabolic Disease.

Insulin-like growth factors in lysosomal storage disease

W. Kiess, E. Froesch, U. Kessler, 2005, European Journal of Pediatrics.

Biochemical, psychometric, and neuropsychological studies in heterozygotes for various lipidoses

K. Betke, J. Martinius, H. Christomanou, 1980, Human Genetics.

Biochemical, genetic, psychometric, and neuropsychological studies in heterozygotes of a family with globoid cell leucodystrophy (Krabbe's disease)

K. Betke, J. Martinius, H. Christomanou, 2004, Human Genetics.

A sensitive fluorescence assay for the simultaneous and separate determination of arylsulphatases A and B.

K. Sandhoff, H. Christomanou, 1977, Clinica chimica acta; international journal of clinical chemistry.

Isolation of two forms of an activator protein for the enzymic sphingomyelin degradation from human Gaucher spleen.

T. Kleinschmidt, H. Christomanou, 1985, Biological chemistry Hoppe-Seyler.

Prenatal diagnosis of tay-sachs disease in cell-free amniotic fluid

K. Sandhoff, H. Christomanou, C. Čáp, 1978, Klinische Wochenschrift.

On the association of excess glycogen granules and polyglucosan bodies (corpora amylacea) in astrocytes of a 17-year-old patient with a neurologic disease of unknown origin: clinical, biochemical, and ultrastructural observations.

L. Palmucci, H. Christomanou, A. Anzil, 1982, Clinical neuropathology.

Saposins (sap) A and C activate the degradation of galactosylceramide in living cells

T. Levade, J. O'brien, M. Hiraiwa, 1997, FEBS letters.

Sphingolipid activator protein 1 deficiency in metachromatic leucodystrophy with normal arylsulphatase A activity. A clinical, morphological, biochemical and immunological study

W. Schlote, J. Seeger, I. Schuster, 1991, European Journal of Pediatrics.

Biochemistry and genetics of gangliosidoses

K. Sandhoff, H. Christomanou, 2004, Human Genetics.

Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies.

Y. Kishimoto, R. Salvayre, T. Levade, 1997, Clinica chimica acta; international journal of clinical chemistry.

Complete amino-acid sequence and carbohydrate content of the naturally occurring glucosylceramide activator protein (A1 activator) absent from a new human Gaucher disease variant.

T. Kleinschmidt, G. Braunitzer, H. Christomanou, 1987, Biological chemistry Hoppe-Seyler.

Variation of arylsulphatase A: comparative studies of arylsulphatase A with synthetic and natural substrates in three families with metachromatic leucodystrophy.

H. Christomanou, Sandhoff, 1978, Neuropadiatrie.

Niemann-Pick disease, Type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside degradation.

H. Christomanou, 1980, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

Wolman's disease: Clinical, biochemical and ultrastructural studies in an unusual case without striking adrenal calcification

K. Sandhoff, G. Janka, H. Christomanou, 1980, European Journal of Pediatrics.

Prenatal monitoring for wolman's disease in a pregnancy at risk

H. Christomanou, C. Čáp, 1981, Human Genetics.

Detection of 8 new mutations in the α-galactosidase A gene in Fabry disease

S. Malcolm, B. Winchester, H. Christomanou, 1994 .

Absence of alpha-fucosidase activity in two sisters showing a different phenotype.

H. Christomanou, D. Beyer, 1983, European journal of pediatrics.

N-terminal amino-acid sequence of a sphingolipid activator protein missing in a new human Gaucher disease variant.

T. Kleinschmidt, G. Braunitzer, H. Christomanou, 1987, Biological chemistry Hoppe-Seyler.

Neutral lipid storage disease—response to dietary intervention

C. Dacou-voutetakis, T. Kakourou, H. Christomanou, 1997, Archives of Disease in Childhood.

Ouchterlony double immunodiffusion method demonstrates absence of ferritin immunoreactivity in visceral organs from nine patients with Niemann-Pick disease type C.

K. Harzer, H. Christomanou, 1996, Biochemical and molecular medicine.

Deficient ferritin immunoreactivity in visceral organs from four patients with Niemann-Pick disease type C.

J. Kellermann, R. Linke, K. Harzer, 1995, Biochemical and molecular medicine.

Structure of full-length cDNA coding for sulfatide activator, a Co-beta-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator.

K. Sandhoff, H. Christomanou, T. Nakano, 1989, Journal of biochemistry.

Complete amino-acid sequence of the naturally occurring A2 activator protein for enzymic sphingomyelin degradation: identity to the sulfatide activator protein (SAP-1).

T. Kleinschmidt, G. Braunitzer, H. Christomanou, 1988, Biological Chemistry Hoppe-Seyler.

AN UNUSUAL FORM OF ARYLSULFATASE A DEFICIENCY COMBINED WITH SULFATIDE‐EXCRETION AND A NORMAL SULFATIDE‐LOADING

T. Burkart, K. B. Nielsen, U. Wiesmann, 1983, Acta paediatrica Scandinavica.

Two Heat-Stable Low-Molecular-Mass Proteins Stimulating the Enzymic Sphingomyelin Degradation Isolated from Human Gaucher and Normal Spleen

H. Christomanou, A. Aignesberger, 1986 .